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INTRODUCTION
FLT3 mutations are common cytogenetic changes in acute
myeloid leukemia (AML). Internal tandem duplication (ITD)
of exon 14 or 15 is detected in 20-30% of patients (1-3) and
a mutation of D835 in exon 20 in 7% of patients (4-7). Many
clinical studies have shown that patients with an ITD at diag-
nosis have frequent disease relapse and a short duration of
survival when compared to patients without an ITD (8-17).
Two prior Korean trials included 165 adult (14) and 61 pedi-
atric (16) patients with AML, and showed similar results;
patients with an ITD at diagnosis had reduced event-free
survival and similar overall survival when compared to pati-
ents without an ITD. The incidence of ITD in the 2 Korean
studies was 35.2% and 6.6%, respectively (14, 16). A second
mutation of FLT3 involves the tyrosine kinase domain (TKD)
at D835. Its incidence is relatively low and its prognostic
value has not been determined (8, 14, 18). However, one of
several studies on TKD showed that the survival of patients
with TKD at diagnosis was longer than those without TKD
(18). 
Several studies have investigated the variability of the FLT3
mutation in patients with AML during treatment (13, 17, 19-
22). When compared to diagnosis, leukemic relapse occurred
with persistent, newly developed or disappeared ITD. Because
of the small number of patients in prior studies, the under-
standing of the FLT3 changes is incomplete. In addition,
the role of the FLT3 status in disease remission or persistence
during therapy has not been evaluated. Therefore, we stud-
ied FLT3 mutations (ITD and TKD) at diagnosis and eval-
uated their variability during disease remission relapse or
persistence with therapy in Korean patients with AML. 
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Low Frequency and Variability of FLT3 Mutations in Korean Patients
with Acute Myeloid Leukemia 
FLT3 mutations are common genetic changes, and are reported to have prognos-
tic significance in acute myeloid leukemia (AML). The FLT3 internal tandem dupli-
cation (ITD) and the D835 activating mutation in the tyrosine kinase domain (TKD)
were analyzed by polymerase chain reaction (PCR) in the genomic DNA of Kore-
an patients with AML at diagnosis and during follow-up. There were 226 patients
with AML enrolled between March 1996 and August 2005. The incidence of ITD
and TKD at diagnosis was 13% (29/226) and 3% (6/226). When compared to West-
ern and other Asian patients with AML, Korean patients had a lower frequency by
about two-thirds of ITD and TKD. Among the non-M3 cases (N=203), the patients
with an ITD had a significantly shorter event-free survival when compared with those
without an ITD (p=0.0079). Among 54 relapsed patients, 9 patients had the FLT3
ITD at diagnosis. Six patients demonstrated a reappearance of the ITD and 3 patients
remained negative at relapse. One patient, among 45 patients who relapsed, had
a negative baseline ITD but acquired a de novo ITD at relapse. There were 101
samples from 93 patients in remission; they were all negative for an ITD. Among
34 patients who failed to achieve a remission, five patients had a persistent ITD
and one patient had a de novo ITD. These results support the concept of resis-
tance of FLT3 ITD leukemic clones to chemotherapy. Therefore, effective therapy
with FLT3 targeting agents may improve the prognosis of non-M3 AML patients
with the FLT3 mutation.
Key Words : FLT3 Mutations; Internal Tandem Duplication; Tyrosine Kinase Domain Mutation; Leukemia,
Myeloid, Acute 
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Eligibility
From March 1996 to August 2005, 226 patients from three
centers were diagnosed with AML and underwent induction
chemotherapy according to the center’s protocol usually includ-
ing anthracycline and cytarabine. Among them, 33 patients
did not receive chemotherapy. Twenty-four patients did not
receive chemotherapy due to co-morbid conditions or advanced
age, and pretreatment mortality occurred in nine patients.
All patients’ bone marrow (BM) samples at diagnosis were
available, but samples after induction were available for 111
patients. BM samples were classified into four groups: Group
A samples at diagnosis, Group B first relapse or more, Group
C first remission or more, and Group D first induction failure
or more. The number of patient samples available at diagnosis
and relapse was 54 for A/B, 91 for A/C and 28 for A/D. All
patients provided informed consent and the individual institu-
tional review boards at each center approved the study protocol.
Detection of FLT3 ITD and TKD
Mononuclear cells from the BM aspirate were isolated
using Histopaque-1077 (Sigma, St. Louis, MO, U.S.A.) and
then DNA was extracted using the QIAmp DNA Blood
Mini Kit (Qiagen, Hilden, Germany). Polymerase chain reac-
tion (PCR) for the ITD was carried out as described previ-
ously (1). We used a 100 ng sample of each patient’s DNA,
which was amplified in a 36-cycle PCR reaction at an anneal-
ing temperature of 56℃. We used 10 μ M/L of two reverse
primers (11R of 5′ -ACTCTA AATTTTCTCT-3′ , and 12R
of 5′ -CTTTCAGCATTTTGACGGCAACC-3′ ) for each
reaction and 10 μ M/ L of a common forward primer (3′ -GC-
AATTTAGGTATGAAAGCCAGC-5′ ). The PCR for TKD
was performed as described previously (3). We amplified
exon 17 of the FLT3 gene by the genomic PCR method
using the primers (17F of 5′ -CCGCCAGGAACGTGC-
TTG-3′ , and 17R of 5′ -GCAG-CCTCACATTGCCCC-
3′ ). Amplified products were digested with Eco RV; then
they were subjected to electrophoresis on an agarose gel.
Statistical analysis
The correlation of the clinical characteristics and the FLT3
ITD or TKD mutations at diagnosis was analyzed in 226
patients with AML, including or excluding those with M3
disease. Differences in the median variables of age, peripher-
al white blood cell (WBC) counts, platelet counts and the
serum lactate dehydrogenase (LDH) concentration were ana-
lyzed by the Mann-Whitney U test. The analysis of data fre-
quencies was performed using the Fisher’s exact test for 2×
2 tables or the chi-square test for larger tables. Survival prob-
abilities were estimated by the Kaplan-Meyer method, and
differences in the survival distributions were evaluated by
the log-rank test. These statistical analyses were performed
with SPSS software, version 13.0 (Chicago, IL, U.S.A.). For
all analyses, the p values were 2-tailed, and a p value of less
than 0.05 was considered statistically significant.
RESULTS
Clinical characteristics of AML patients with or without
FLT3 mutations
Among the 226 AML patients, 29 (12.8%) had an ITD,
6 (2.7%) had a TKD and 191 (84.5%) had neither (wild type).
No patient had an ITD and TKD concomitantly. When
compared to patients with the wild type, the patients with
an ITD or a TKD were significantly older (p=0.020) and
had higher WBC (p=0.008) counts. Their subtypes were
most frequently from M0 to M5. The presence of FLT3 muta-
tions was not related to gender, previous hematological dis-
ease, cytogenetic changes, or high serum LDH (Table 1). 
The effect of FLT3 mutations on remission and survival
Among the 193 patients receiving induction chemother-
apy, 182 patients were available to evaluate for remission and
151 patients achieved complete remission; the remission
rate (RR) was 78%. Nine patients died of therapy-related
complications within 30 days. Among 22 patients with an
ITD at diagnosis, 19 patients achieved remission. There was
no significant difference in the RR between patients with an
ITD and the wild type (p=0.651). Therefore, the presence of
a FLT3 mutation did not influence the RR (p=0.824).
At a median follow-up of 61 (11-123) months, 90 of the
236 patients (39.8%) were still alive. The median overall sur-
vival (OS) was 14 (95% CI, 12-17), 14 (4-23) and 14 (10-18)
months in all patients, those with an ITD and those with the
wild type, respectively (p=0.530). The median event-free sur-
vival (EFS) was 10 (8-12), 7 (2-11) and 11 (7-14) months for
all patients, those with an ITD and those with the wild type,
respectively (p=0.094). When excluding the M3 types (N=
20), comparison of the OS between the ITD and wild type
patients showed no difference; however, the EFS with an ITD
was significantly shortened (p=0.0079, Fig. 1). In the multi-
variate analysis in treated non-M3 patients (N=176), the sig-
nificant factors influencing the OS and the EFS were cyto-
genetic risk group (23), the presence of a complete remission
after the first induction and post-remission transplantation
either autologous or allogeneic (Table 2). However, neither a
FLT3 mutation nor an ITD affected survival in this analysis.
Variability of the FLT3 mutation
The changes of the FLT3 ITD are summarized in Fig. 2.
834 S.-M. Bang, J.Y. Ahn, J. Park, et al.At hematological remission, all samples were negative for an
ITD even if there was an initially positive ITD (N=14). The
ITD reappeared with relapse in 6 out of 9 patients, and was
de novo in one of 45 patients. Induction failures with a per-
sistent ITD were common. One patient had a lately occurred
ITD at the second induction failure. The TKD changes were
evaluated in patients from one center. Among 23 samples at
relapse, two had a TKD. One patient had a TKD initially,
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Total (N=226) FLT3 (+)* (N=35) Wild type (N=191) p value
Age; median (range) 35 (0-86) 46 (5-86) 32 (0-85) 0.020
Sex: male/female 118/108 14/21 104/87 0.116
Secondary leukemia 16 11 5 0.289
Subtypes 0.001
M0/1/2/3/4/5 6/24/86/20/33/21 4/6/9/7/3/5 2/18/77/13/30/16
M6/7/RAEB-t/mixed
� 13/16/2/5 0/0/0/1 13/16/2/4
Cytogenetics (N=185) 0.209
Favorable 52 8 44
Intermediate 109 18 91
Adverse 24 1 23
CBC: median (range)
Hemoglobin (g/dL) 7.3 (1.5-13.5) 7.9 (3.5-13.3) 7.1 (1.5-13.5) 0.343
White blood cells (/μ L) 12,740 (250-497,280) 51,990 (630-497,280) 8,495 (250-292,900) 0.008
Platelets (×1,000/μ L) 38 (3-315) 44 (8-315) 37 (3-302) 0.664
LDH: median (range) (IU/L) 910 (246-7,365) 1,600 (374-5,007) 910 (246-7,365) 0.153
Table 1. Patient and disease characteristics according to FLT3 mutational status 
*, FLT3 internal tandem duplication (ITD) or D835 point mutation of tyrosine kinase domain (TKD) was identified in this group; 
� , mixed means biphe-
notypic or bilineage leukemia.
RAEB-t, refractory anemia with excess blast in transformation; CBC, complete blood count; LDH, latacte dehydrogenase.
EFS
p value HR 95.0% CI for HR
OS
p value HR 95.0% CI for HR
Age 0.406 1.140 0.837 1.553 0.150 1.248 .923 1.688
Cyto 0.001 1.798 1.276 2.535 0.005 1.608 1.151 2.247
1st CR 0.000 1.519 1.246 1.851 0.000 1.653 1.394 1.959
SCT 0.001 1.773 1.280 2.455 0.002 1.704 1.222 2.377
Table 2. Multivariate analysis of the significant factors for event-free (EFS) and overall survival (OS) in treated non-M3 patients (N=176)
HR, hazard ratio; Cyto, cytogenetic 3 risk groups consisted of favorable, intermediate, and adverse risk groups; 1st CR, complete hematologic remis-
sion to the first induction treatment; SCT, stem cell transplantation.
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Fig. 1. Event-free survival according to FLT3-ITD in 206 patients
with non-M3 AML. 
Fig. 2. Changes of FLT3-ITD during follow-up.
ITD
+, FLT3-ITD positive, and ITD
-, FLT3 wild type. A (numeral)/B
(numeral) means a number of patients with FLT3-ITD/tested
patients. 
ITD
+
N=29
At relapse
6/9 reappeared
At relapse
1/45 acquired
Induction failure
1/28
Induction failure
2/2 primary refractory
3/4 relapsed
ITD
-
N=197
At remission
0/14 (19 sample tested)
At remission
0/79 (82 tested)and it reappeared on relapse. The other patient had an ITD
only at diagnosis, and showed a newly appeared TKD at
remission, which persisted at relapse and during the refrac-
tory period despite negative conversion of ITD.
DISCUSSION
Our study showed a low frequency of FLT3 ITD and TKD,
12.8% and 2.7%, respectively, in Korean AML patients. This
frequency was about two-thirds lower than reports from other
Asian and Western patients. (1, 2, 4, 8-13, 19, 24). A recent
Korean study on M3 disease showed a relatively low fre-
quency of ITD and TKD, 12.0% and 9.3% (25). Another
unpublished Korean report also showed a low frequency of
the FLT3 mutation in AML patients, the ITD was 10.4%
and the TKD was 9.1% (26). To determine the association
with age, we separated the patients into 148 adults and 72
pediatric patients. The adult group had the FLT3 mutation
in 16% of cases and the pediatric group in 6%. Previous
reports showed the FLT3 mutation in 20-30% of adults
and in 9-11.5% of pediatric aged patients (27, 28). There-
fore, the information to date shows that the frequency of the
FLT3 mutation, especially the ITD, is low in Korean AML
patients in both the adult and pediatric age groups.
The prognostic value of the FLT3 mutation in AML was
evaluated in a group of patients with normal karyotypes
excluding those with known prognostic cytogenetic changes.
About half of the AML patients had a normal karyotype or
an intermediate cytogenetic risk (24, 29). The FLT3 ITD at
diagnosis in these patients was associated with a significant-
ly shortened EFS and OS (8-17). Therefore, intensified con-
solidation including transplantation or clinical trials target-
ing the FLT3 mutation should be considered in patients
with an ITD (30, 31). The variability of the FLT3 ITD, dur-
ing treatment in this study, supports a pattern of reappear-
ance of the ITD with disease relapse and persistent ITD in
refractory disease, which suggests chemo-resistance of the
ITD-positive leukemic clones. 
Our study included only 20 patients with M3. Recently
several studies reported that M3 patients with ITD had a
poor survival (25, 32). Clinical trials with FLT3-targeting
agents to ATRA and anthracycline-based treatment may pro-
vide more information on the role of FLT3 in M3.
Although a more sensitive method for detection of ITD,
such as the genescan technique, (21) was not used in our trial,
all samples at remission were negative for ITD. In a follow-
up to our study (data not included) genescan detected ITD
in three out of 101 samples at remission. Therefore, future
studies should use the more sensitive methods now available
instead of the PCR.
In summary, this study included the largest number of
Korean patients with AML to date, and showed a relatively
low frequency of FLT3 ITD consistent with prior reports. ITD
in Korean non-M3 AML patients was associated with poor EFS.
In addition, the variability of ITD, during treatment follow-
up, suggested chemo-resistance of the ITD-positive leukemic
clones. Therefore, aggressive therapeutic approaches should
be considered in AML patients with ITD at diagnosis.
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